Ryvu Therapeutics (FRA:9Y4) LT-Debt-to-Total-Asset : 0.20 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ryvu Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ryvu Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.20.

Ryvu Therapeutics's long-term debt to total assets ratio increased from Dec. 2023 (0.00) to Dec. 2024 (0.20). It may suggest that Ryvu Therapeutics is progressively becoming more dependent on debt to grow their business.

Ryvu Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Ryvu Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics LT-Debt-to-Total-Asset Chart

Ryvu Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

0.20

Ryvu Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	0.07	0.13	0.18	0.20

Ryvu Therapeutics LT-Debt-to-Total-Asset Calculation

Ryvu Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	18.515	/	93.853
	=	0.20

Ryvu Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	18.515	/	93.853
	=	0.20

Ryvu Therapeutics (FRA:9Y4) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ryvu Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ryvu Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (FRA:9Y4) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

RVU:Poland

Address

Leona Henryka Sternbacha 2, Krakow, POL, 30-394

Website

https://www.ryvu.com

Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics Headlines

No Headlines